No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies by de Beukelaar, Janet W. et al.
Cancer Immunol Immunother (2007) 56:1501–1506 
DOI 10.1007/s00262-007-0295-2
123
ORIGINAL ARTICLE
No evidence for circulating HuD-speciWc CD8+ T cells in patients 
with paraneoplastic neurological syndromes and Hu antibodies
Janet W. de Beukelaar · Georges M. Verjans · Yvette van Norden · 
Johannes C. Milikan · Jaco Kraan · Herbert Hooijkaas · Kees Sintnicolaas · 
Jan W. Gratama · Peter A. Sillevis Smitt 
Received: 16 November 2006 / Accepted: 23 January 2007 / Published online: 14 February 2007
© Springer-Verlag 2007
Abstract
Aim In paraneoplastic neurological syndromes
(PNS) associated with small cell lung cancer (SCLC)
and Hu antibodies (Hu-PNS), Hu antigens expressed
by the tumour hypothetically trigger an immune
response that also reacts with Hu antigens in the
nervous system, resulting in tumour suppression and
neuronal damage. To gain more insight into the hypoth-
esized CD8+ T cell-mediated immune pathogenesis of
these syndromes, we searched for circulating HuD-spe-
ciWc CD8+ T cells in a large cohort of Hu-PNS patients
and controls.
Patients and methods Blood was tested from 43 Hu-
PNS patients, 31 Hu antibody negative SCLC patients
without PNS and 54 healthy controls. Peripheral blood
mononuclear cells (PBMC) were stimulated with HuD
protein-spanning peptide pools (15-mers) and individ-
ual HuD-derived peptides (9-mers) and analysed by
cytokine  Xow cytometry and interferon- ELISPOT-
assays. Additionally, HuD-based Class I HLA multi-
mers were used to visualize HuD-speciWc CD8+ T cells.
Results No HuD-speciWc CD8+  T cells could be
detected in the blood of Hu-PNS patients or controls.
Conclusions Our results do not support a role for
HuD-speciWc CD8+ T cells in Hu-PNS. Further studies
should focus on the detection of circulating HuD-spe-
ciWc CD4+ T cells and examine the antigen speciWcity of
T cells in aVected tissues.
Keywords Paraneoplastic · Anti-tumour immunity · 
T lymphocyte · SCLC · HuD · HLA class I multimer
Introduction 
Paraneoplastic neurological syndromes (PNS) are con-
sidered as naturally occurring, successful anti-tumour
immune responses in humans [6]. However, this
tumour immunity goes along with autoaggression
against the nervous system, resulting in severe neuro-
logical dysfunction [9]. The mechanisms responsible
for the anti-tumour response and neuronal damage are
poorly understood. Antigens expressed by the tumour
that are normally restricted to neurons (so-called
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onconeuronal antigens) hypothetically trigger an
immune response that cross-reacts with the same anti-
gens in the nervous system [7]. One of the most fre-
quently involved tumours is small cell lung cancer
(SCLC) and approximately 50% of patients with PNS
and SCLC have high-titre Hu antibodies (Hu-PNS).
Hu antibodies are directed against a family of neuron
speciWc, mRNA binding proteins, of which HuD is the
best-documented member. Consistent expression of
HuD in all SCLC suggests that HuD plays a central
role in triggering the immune response [15, 17].
High titres of Hu antibodies in serum and cerebro-
spinal Xuid suggested a pathogenic role for these anti-
bodies, that could, however, never be proven in animal
models [3, 22]. Furthermore, expression of Hu antigens
is exclusively intracellular, and it is therefore diYcult to
understand how such antibodies could target tumours
or neurons [5]. In addition, pathological examination
of PNS neuronal tissue demonstrated localized inXam-
matory cell inWltrates, containing B cells, CD4+ and
CD8+ T cells, in the proximity of overt neuronal cell
damage [2, 13, 18, 25]. The presence of an oligoclonal
CD8+ T cell inWltrate in nervous tissues and tumours of
Hu-PNS patients further suggests an immunopatho-
genic role for such cells [18, 25].
Some authors report the presence of HuD peptide-
speciWc CD8+ T cells in the blood of these patients, but
also in that of apparently healthy controls (HC) [19, 20,
24]. In addition, the presence of circulating HuD-spe-
ciWc CD4+ T cells has been suggested [1].
Here, we have investigated the presence of circulat-
ing HuD-speciWc T cells in a large cohort of Hu-PNS
patients and controls. Despite a multifaceted approach
mainly geared towards the detection of HuD-reactive
CD8+ T cells and, to a somewhat lesser extent, CD4+ T
cells, no such cells were detected in the blood of Hu-PNS
patients and controls.
Materials and methods
Patients
Forty-three patients with high-titred Hu antibodies and
a deWnite clinical diagnosis of PNS [12], 31 Hu anti-
body negative SCLC patients without neurological
symptoms or signs (SCLC) and 54 apparently HC
were tested. The Erasmus MC Institutional Review
Board approved the study and all individuals provided
written informed consent. The individuals’ class I HLA
alleles were typed by standard diagnostic PCR at the
two-digit resolution level. Patient characteristics are
shown in the Table 1. Anti-Hu IgG titres were
determined as described previously [21] and in Hu-
PNS the dependence in activities of daily living was
scored using the modiWed Rankin scale [21]. Twenty-
Wve HC were male and 29 female, their median age was
46 years (range 17–89) and all were Hu antibody nega-
tive. No HC had received previous chemotherapy or
immunosuppressive treatment and 30 HC (56%) were
CMV-seropositive.
Reagents
Ninety-three HuD protein-spanning synthetic pep-
tides, 15-mers with 11 amino acids overlap, were
pooled to constitute the HuD peptide mix (HuDmix)
and smaller peptide pools [Jerini Peptide Technologies
(JPT), Berlin, Germany]. For interferon- enzyme-
linked immunosorbent spot-forming (IFN- ELI-
SPOT) assays and the construction of HLA class-I
multimers, HuD-derived 9- and 10-mers were selected
based on previous studies [19, 20]. The phycoerythrin
(PE)-labeled multimers and corresponding peptides
used were: HLA-A*0101-147ELEQLFSQY155, HLA-
A*0101-245RLDNLLNMAY254, HLA-A*0201-86SLG
YGFVNYI95, HLA-A*0201-248NLLNMAYGV256, HL
A-A*0201-315QLFGPFGAV323, HLA-A*0201-362RLG
DRVLQV370, and HLA-A*2402-154QYGRIITSRI163
(ProImmune, Oxford, UK). As positive and negative
controls, HLA-A*0201-495NLVPMVATV503 [CMV
phosphoprotein-65 (CMV-pp65); Beckman Coulter,
San Diego, CA] and HLA-A*0201 presenting an
irrelevant peptide (ProImmune), respectively, were
included.
To measure general T-cell responsiveness, we used
phorbol myristate acetate (PMA) plus ionomycin, or
phytohemagglutinin (PHA). A peptide pool containing
15-mers spanning CMV-pp65 (JPT) was used as posi-
tive- and negative antigen-speciWc control in CMV
seropositive and seronegative individuals, respectively.
Cytokine Xow cytometry
Peripheral blood mononuclear cells (PBMC) were
isolated within 12 h after venipuncture and stimulated
in duplicate as described elsewhere [14]. BrieXy,
2 £ 106 PBMC were incubated at 37°C in a CO2
incubator for 18 h with 1 g/ml HuDmix, 1 g/ml
CMV-pp65, 1 g/ml ionomycin plus 25 ng/ml PMA, or
without antigen. After 2 h of stimulation, brefeldin A
was added to one of the duplicate tubes allowing for
intracellular accumulation of cytokines in activated
T cells. Brefeldin A was not added to the second tube
to allow detection of secreted cytokines in the super-
natant. In some individuals, additional stimulation wasCancer Immunol Immunother (2007) 56:1501–1506 1503
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performed in the presence of co-stimulatory monoclonal
antibodies (mAb) directed against CD28 and CD49d
(BD Biosciences, San Jose, CA). Stimulated PBMC
were stained and analysed using anti-CD3 conjugated
with peridinyl chlorophyllin (PerCP), anti-CD8 conju-
gated with allophycocyanin (APC), anti-interferon
(IFN)- conjugated with Xuorescein isothiocyanate
(FITC), anti-tumour necrosis factor (TNF)- conju-
gated with PE, or appropriate isotype control mAb (all
from BD Biosciences) [14]. CD4+ T cells were deWned
as CD3+, 8¡. Positive responses were deWned by (1)
percentage of cytokine-positive CD4+ or CD8+ T cells
>2 times the negative control (i.e., no antigen) and (2)
¸0.1% of the total number of CD4+ or CD8+ T cells,
each after subtraction of isotype control results.
Detection of secreted cytokines
The secretion levels of IFN-, TNF-, interleukin
(IL)-2, IL-4, IL-5 and IL-10 were measured in super-
natants using a cytometric bead array (BD Bio-
sciences). Based on CMV data (not shown), a positive
result was deWned as cytokine concentration >2 times
the background (no antigen) and a minimum level of
50 pg/ml.
IFN- ELISPOT
PBMC (2 £ 105/well) were pre-stimulated in dupli-
cate in 96-well plates with culture medium containing
3 g/ml HuD 9-mers, HuDmix, CMV-pp65, PHA, or
no antigen for 1.5 h at 37°C and 5% CO2 [10]. The
PBMC were subsequently transferred to anti-IFN-
-coated ELISPOT plates (Nalge Nunc, Rochester,
NY) for a further 18-h incubation. The ELISPOT
assay was performed using standard protocols and
automated reading (AELVIS GmbH, Hanover, Ger-
many) [10]. The mean number of spot-forming cells
(SFC) in duplicate wells was used as assay outcome.
Positive results were deWned by numbers of SFC/well
>3 times background (no antigen) and a minimum of
15 SFC/well.
Detection of HuD-speciWc CD8+ T cells using Class-I 
HLA multimers
Thawed PBMC were stained as described previously
[11]. Following acquisition of 1 £ 105 viable (i.e., 7-
amino-actinomycin-D [7AAD] negative) CD8+ T
cells, a positive result required a percentage of
¸0.1% of viable CD8+ T cells binding the HuD multi-
mer and a brightly staining HuD multimer-binding
CD8+ T-cell population that did not overlap with the
dimly staining irrelevant multimer-binding T-cell
population.
Table 1 Patient characteristics at the time of study entry
Hu-Ab Hu antibody, CMV cytomegalovirus, pos positive, neg
negative, NA not applicable, PSN paraneoplastic sensory neuron-
opathy, PEM paraneoplastic encephalomyelitis, PCD paraneo-
plastic cerebellar degeneration, PLE paraneoplastic limbic
encephalitis, BE brainstem encephalitis, SCLC small cell lung
cancer, NSCLC non-small cell lung cancer, MRS modiWed Ran-
kin score
a  One Hu-PNS patient was a 4-year-old boy with an underlying
neuroblastoma. The remaining Hu-PNS patients were aged be-
tween 49 and 81 years
b  No tumour mass visible on CT-scan or FDG-PET scan
c  Median (ranges) of intervals are shown
d  Progression of neurological symptoms was deWned by the in-
crease of at least one point on the modiWed Rankin scale during
2 months prior to study entry
Hu-PNS SCLC 
N4 3 3 1
Age (median, range) 64 (4–81)a 61 (40–83)
Gender (M/F) 15/28 21/10
Hu-Ab titre (median, 
range)
12,800 
(400–204,800)
Negative
CMV serostatus 
(pos/neg)
29/14 17/14
Paraneoplastic 
neurological syndrome
NA
PSN 27
PEM 5
PCD 4
PLE/ BE 3
Pseudo-obstruction 2
Motor neuron disease 2
Tumour
No tumour 8b 0
SCLC 31 31
Limited 28 17
Extended 3 14
NSCLC 2 0
Prostate 1 0
Neuroblastoma 1 0
Prior treatment
None 27 27
Chemotherapy §
immunosuppression
16 4
Neurological symptoms NA
Interval onset symptoms 
(study entry)
5 months (2–15)c
Interval onset symptoms 
(diagnosis)
4 months (1–12)c
Progressive at study 
entryd
34 (79%)
ModiWed Rankin score NA
MRS = 2 7
MRS = 3 22
MRS = 4 10
MRS = 5 41504 Cancer Immunol Immunother (2007) 56:1501–1506
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Results
Cytokine Xow cytometry of PBMC after stimulation 
with HuD-derived peptides
Stimulation with PMA and ionomycin induced IFN-
production in both CD4+ and CD8+ T cells of all indi-
viduals (not shown). Whilst all CMV-seropositive
individuals speciWcally responded to CMV-pp65, no
HuD-speciWc T-cell reactivity was observed in any of
the Hu-PNS patients, SCLC patients or HC (Fig. 1a,
b). Similar results were obtained when intracellular
TNF- (not shown) or secreted cytokines (Fig. 1c)
were measured. The use of co-stimulatory antibodies
in combination with HuDmix did not result in the
detection of HuD-speciWc T-cell reactivity (not
shown).
IFN-ELISPOT assay on PBMC stimulated 
with HuD-derived 9-mers
All individuals responded to PHA as determined by
IFN-ELISPOT assay. In addition, all CMV-seroposi-
tive individuals responded to CMV-pp65. However, no
T cell reactivity towards the previously described class-
I HLA-binding HuD peptides [20] was detected in
individuals with the appropriate HLA types in any of
the study groups (Fig. 1d).
Analysis of HuD-speciWc CD8+ T cells using Class-I 
HLA multimers
Finally, we investigated the presence of HuD-speciWc
CD8+ T cells in PBMC using Class-I HLA multimers con-
taining HuD-derived peptides. Whilst CMV-seropositive
Fig. 1 Cytokine production in response to HuDmix and HLA-
matched HuD 9-mers. Proportions of CD8+ (panel a) and CD4+
(panel b) T cells expressing intracellular IFN- after stimulation
with HuDmix in Hu-PNS patients, SCLC and healthy controls.
Each dot represents the result observed in a single individual
(panel c). After stimulation of PBMC with HuDmix and control
antigens, the indicated cytokines were measured in assay
supernatants. The results are shown for Hu-PNS patients only.
Horizontal lines indicate median values of each group (panel d).
ELISPOT assay showing the number of IFN- SFC after stimula-
tion of 2 £ 105 PBMC with HuDmix or HuD 9-mers. Each dot
represents the mean result of duplicates for each stimulus in each
individual (panels a–d). Responses to CMV antigens are shown
for CMV seropositive individuals only, as they were consistently
negative in CMV seronegative individuals (not shown). The num-
bers of individuals tested are given in between brackets. NEG
negative control (incubation without antigen), HuDmix HuD
protein-spanning peptide pool, PP65 CMV pp-65 protein-span-
ning peptide pool, IL interleukin TNF tumour necrosis factor,
IFN interferon, SFC spot-forming cell, PHA phytohemaggluti-
nin. ELE, RLD, SLG, NLL, QLF, RLG and QYG designate
individual HuD-based peptidesCancer Immunol Immunother (2007) 56:1501–1506 1505
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individuals with the appropriate HLA types showed
distinct populations of pp65 multimer-binding CD8+ T
cells, no HuD-speciWc CD8+ T cells were observed in
individuals with the appropriate HLA types in any of
the study groups (Fig. 2).
Discussion
We set out to detect HuD-speciWc T cells in the blood
of Hu-PNS patients as they are postulated to play a
pivotal role in the immunopathology of this disease.
Although we applied three diVerent approaches we
could not detect circulating HuD-speciWc T cells.
First, to induce cytokine responses in T cells, we used
15-mer protein-spanning peptide pools that have the
advantage of covering the full protein sequence and of
eliciting both CD8+ and CD4+ T-cell responses [14],
as demonstrated by the CD8+ and CD4+ CMV-pp65-
speciWc T-cell responses. However, no CD8+ or CD4+
HuD-speciWc T-cell responses were observed. These
results are at variance with the detection of HuD-spe-
ciWc CD4+ T-cell proliferative responses in PBMC of
Hu-PNS patients by Benyahia et al. [1]. This discrep-
ancy may be explained by diVerences in read-out (i.e.,
3-day lymphocyte proliferation in Benyahia’s study [1]
vs. overnight cytokine production in ours) and the use
of recombinant HuD protein [1] versus a protein-span-
ning 15-mer peptide pool (this manuscript).
We then studied responses to HLA class-I binding
HuD peptides that were previously selected [20]. Using
the same experimental setup and HuD 9-mer peptides,
Rousseau et al. [20] reported HuD-speciWc T-cell reac-
tivity in 7/10 Hu-PNS patients and in 3/10 HC [20]. In
that small study a positive response was deWned as an
experimental value ¸2 times above background. With
that criterion, 3 PNS, 2 SCLC and 4 HC would have
been classiWed as HuD T-cell responders in our study.
However, using that cut-oV w e  w o u l d  a l s o  h a v e
detected T-cell reactivity in individuals whose Class-I
HLA molecules did not have the appropriate binding
motifs (data not shown). Therefore, we used more
stringent cut-oV levels resulting in a negative outcome.
As most patients in both studies had progressive neu-
rological disease and were tested shortly after start of
symptoms and prior to therapy, diVerences between
the study populations do not explain this discrepancy.
Finally, we could not detect HuD-speciWc circulating
CD8+ T cells using Class-I HLA multimers with the
same  Wne speciWcities as deWned by Rousseau et al.
[20].
The absence of detectable circulating HuD-speciWc
CD8+ T cells may not be surprising. In a PCR-based
study, Plonquet et al. [18] detected the same T-cell
clone in neoplastic and nervous tissues, but not in
blood. This Wnding suggests that T cells involved in the
pathogenesis of Hu-PNS circulate in concentrations
below detection level. An immune response taking
place in the central nervous system parenchyma may
deplete the circulating pool of CD8+ T cells with that
speciWcity [23]. Furthermore, vaccination studies in
melanoma patients demonstrate that clinically eVective
anti-tumour immune responses may occur despite low
levels of melanoma-speciWc cytotoxic T cells, i.e.,
below the detection limit of multimer-based assays [4,
16].
Fig. 2 Analysis of HuD peptide-loaded, Class-I HLA multimer-
binding CD8+ T cells. PBMC from a CMV-seropositive Hu-PNS
patient were stained with HLA-A*0201 multimers loaded with
the HuD peptide SLGYGFVNYI (panel a), an irrelevant peptide
(panel b) or with the CMV-pp65 peptide NLVPMVATV (panel
c). All data shown are obtained after selection of T cells (i.e.,
CD3+, low sideward scatter signals) [12]. Binding of Class-I HLA
multimers (panels a–c, horizontal axes) was analysed in relation
to CD8 expression. In this example, the proportion of SLGYG-
FVNYI multimer-binding CD8+ T cells (0.36%) was similar to
that of irrelevant multimer-binding CD8+ T cells (0.46%); bind-
ing resulted in low-intensity Xuorescence signals only. In contrast,
2.46% of CD8+ T cells bound the NLVPMVATV multimer
resulting in high-intensity Xuorescence signals from most CD8+ T
cells1506 Cancer Immunol Immunother (2007) 56:1501–1506
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In conclusion, we were unable to detect HuD-spe-
ciWc T cells in a large cohort of Hu-PNS patients and
controls. However, two of our three assays were
designed for the detection of CD8+ T cells only. The
IgG1 isotype predominance of serum Hu antibodies in
Hu-PNS indicates a T-helper response to the Hu anti-
gen [13]. Therefore, further studies are warranted that
focus on the detection of circulating HuD-speciWc
CD4+ T cells. In this context, regulatory CD4+ T cells—
which down regulate immune responses towards auto-
antigens and tumour-antigens—are of interest. Although
the numbers of regulatory T cells are increased in can-
cer patients [26] and in PNS patients [8] (de Beukelaar
et al. unpublished data) their (possibly impaired) func-
tion in PNS remains to be studied. Finally, examination
of the antigen-speciWcity of T cells in aVected tissues
may shed further light on the role of HuD-speciWc T
cells in the pathogenesis of Hu-PNS.
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